Advertisement

Topics

Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

04:14 EDT 14 Jun 2018 | SCRIP

The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints...

      

Related Stories

 

Original Article: Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

NEXT ARTICLE

More From BioPortfolio on "Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data"

Advertisement
Quick Search
Advertisement
Advertisement